Literature DB >> 6458355

Estrogenic effects of physiological concentrations of 5-androstene-3 beta, 17 beta-diol and its metabolism in MCF7 human breast cancer cells.

J Adams, M Garcia, H Rochefort.   

Abstract

5-Androstene-3 beta, 17 beta-diol (ADIOL) has previously been shown to have a high affinity for the estrogen receptor and to translocate it to the nucleus in vitro and in vivo. This compound and related C19 delta 5-steroids of adrenal origin have now been examined for their ability to induce the synthesis in MCF7 cells of an estrogen-dependent secreted glycoprotein (M.W. 46,000). Concentrations required for half-maximum induction were 2 nM for ADIOL and 500 nM for dehydroepiandrosterone (DHEA). Dehydroepiandrosterone sulfate showed weak inducing ability at concentrations of 1 microM or greater. The induction by ADIOL was unaffected by the presence of an aromatase inhibitor, and 5 alpha-androstane-3 beta, 17 beta-diol, which cannot be aromatized, also induced the M.W. 46,000 protein at low concentrations. When cells were exposed to 10 nM [3H]ADIOL, the cytosol and nuclear fractions contained [3H]ADIOL resistant to charcoal adsorption. The bound [3H]ADIOL in the cytosol and nucleus was displaceable by 17 beta-estradiol and tamoxifen, suggesting that it was binding to the estrogen receptor. [3H]ADIOL was metabolized to its 3 beta-sulfate, which was excreted into the medium, and to [3H]DHEA, which was found in the cells and the medium as free DHEA and its 3 beta-sulfate. [3H]DHEA was also metabolized by the cells to its 3 beta-sulfate, to free ADIOL, and to the 3 beta-sulfate of adiol. We conclude that: (a) ADIOL is effective as an estrogen in MCF7 cells at a concentration of 2 nM, which is within the range found in the blood of normal women; and (b) sulfurylation is a major route of inactivation of 3 beta-hydroxy delta 5-steroids in MCF7 cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6458355

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells.

Authors:  S Yeh; H Y Kang; H Miyamoto; K Nishimura; H C Chang; H J Ting; M Rahman; H K Lin; N Fujimoto; Y C Hu; A Mizokami; K E Huang; C Chang
Journal:  Endocrine       Date:  1999-10       Impact factor: 3.633

2.  Modulation of higher-primate adrenal androgen secretion with estrogen-alone or estrogen-plus-progesterone intervention.

Authors:  Alan J Conley; Frank Z Stanczyk; John H Morrison; Pawel Borowicz; Kurt Benirschke; Nancy A Gee; Bill L Lasley
Journal:  Menopause       Date:  2013-03       Impact factor: 2.953

3.  Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.

Authors:  H Miyamoto; S Yeh; H Lardy; E Messing; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

4.  Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer.

Authors:  Xiaoqiang Wang; Catherine Gérard; Jean-François Thériault; Donald Poirier; Charles J Doillon; Sheng-Xiang Lin
Journal:  J Mol Cell Biol       Date:  2015-05-12       Impact factor: 6.216

5.  Androstenedione and androst-5-ene-3 beta,17 beta-diol stimulate DMBA-induced rat mammary tumors--role of aromatase.

Authors:  S Dauvois; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

6.  Adrenal steroids stimulate growth and progesterone receptor levels in rat uterus and DMBA-induced mammary tumors.

Authors:  P G Spinola; B Marchetti; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

7.  Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARalpha and NF-kappaB.

Authors:  Robin Altman; Deborah D Motton; Rama S Kota; John C Rutledge
Journal:  Vascul Pharmacol       Date:  2007-12-15       Impact factor: 5.773

8.  Dehydroepiandrosterone and estrone 17-ketosteroid reductases in MCF-7 human breast cancer cells.

Authors:  J H MacIndoe; M Hinkhouse; G Woods
Journal:  Breast Cancer Res Treat       Date:  1990-10       Impact factor: 4.872

9.  Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor Irosustat (STX64, BN83495).

Authors:  L W Lawrence Woo; Dharshini Ganeshapillai; Mark P Thomas; Oliver B Sutcliffe; Bindu Malini; Mary F Mahon; Atul Purohit; Barry V L Potter
Journal:  ChemMedChem       Date:  2011-08-25       Impact factor: 3.466

10.  5-En-androstene-3 beta,17 beta-diol inhibits the growth of MCF-7 breast cancer cells when oestrogen receptors are blocked by oestradiol.

Authors:  G Boccuzzi; E Brignardello; M Di Monaco; V Gatto; L Leonardi; A Pizzini; M Gallo
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.